Literature DB >> 34722822

Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement Pathway.

Wioleta M Zelek1.   

Abstract

The complement system is a central component of innate immunity, responsible for recognition and killing of bacteria by tagging invaders through opsonisation, thereby promoting phagocytosis, and by direct lysis. Complement activity is routinely measured using functional assays that utilise erythrocytes as targets. The classical pathway haemolytic assay (CH50) with antibody sensitised sheep erythrocytes as target is used worldwide in clinical and research laboratories to measure complement activity in human and rodent sera. While there are no particular limitations in the human assay, measuring complement in mouse serum is more difficult and usually requires large amounts of serum, which is challenging to collect in experiments. In particular, it is challenging to measure the activities of individual mouse complement proteins. To overcome this hurdle, we have developed protocols that employ human sera depleted of single complement proteins as the source of the other complement proteins and test mouse serum to restore the relevant component. This simple haemolytic assay is a useful tool for confirming natural or engineered complement deficiencies and complement dysregulation in mouse models.
Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Assay; CH50; Classical; Complement; Depleted sera; Haemolytic; Mouse

Year:  2021        PMID: 34722822      PMCID: PMC8517650          DOI: 10.21769/BioProtoc.4175

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  14 in total

Review 1.  Compendium of current complement therapeutics.

Authors:  Wioleta M Zelek; Long Xie; B Paul Morgan; Claire L Harris
Journal:  Mol Immunol       Date:  2019-08-22       Impact factor: 4.407

2.  Integrated structural and evolutionary analysis reveals common mechanisms underlying adaptive evolution in mammals.

Authors:  Greg Slodkowicz; Nick Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

Review 3.  Membrane attack by complement.

Authors:  E R Podack; J Tschopp
Journal:  Mol Immunol       Date:  1984-07       Impact factor: 4.407

4.  Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers.

Authors:  Wioleta M Zelek; Claire L Harris; B Paul Morgan
Journal:  Immunobiology       Date:  2018-07-20       Impact factor: 3.144

Review 5.  Genomic view of the evolution of the complement system.

Authors:  Masaru Nonaka; Ayuko Kimura
Journal:  Immunogenetics       Date:  2006-08-09       Impact factor: 2.846

Review 6.  Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.

Authors:  Sarah M Carpanini; Megan Torvell; Bryan Paul Morgan
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

7.  Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species.

Authors:  Wioleta M Zelek; Philip R Taylor; B Paul Morgan
Journal:  Immunology       Date:  2019-06-17       Impact factor: 7.397

8.  Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species.

Authors:  Wioleta M Zelek; B Paul Morgan
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 8.786

9.  Mouse complement: the effect of sex hormones and castration on two of the late-acting components.

Authors:  W H Churchill; R M Weintraub; T Borsos; H J Rapp
Journal:  J Exp Med       Date:  1967-04-01       Impact factor: 14.307

10.  Structural basis of complement membrane attack complex formation.

Authors:  Marina Serna; Joanna L Giles; B Paul Morgan; Doryen Bubeck
Journal:  Nat Commun       Date:  2016-02-04       Impact factor: 14.919

View more
  2 in total

1.  Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.

Authors:  Sarah M Carpanini; Megan Torvell; Ryan J Bevan; Robert A J Byrne; Nikoleta Daskoulidou; Takashi Saito; Takaomi C Saido; Philip R Taylor; Timothy R Hughes; Wioleta M Zelek; B Paul Morgan
Journal:  Acta Neuropathol Commun       Date:  2022-07-06       Impact factor: 7.578

2.  Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients.

Authors:  Eleonora Lekova; Wioleta M Zelek; David Gower; Claus Spitzfaden; Isabelle H Osuch; Elen John-Morris; Lasse Stach; Darren Gormley; Andrew Sanderson; Angela Bridges; Elizabeth R Wear; Sebastien Petit-Frere; Michael N Burden; Richard Priest; Trevor Wattam; Semra J Kitchen; Maria Feeney; Susannah Davis; B Paul Morgan; Eva-Maria Nichols
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.